Cyclacel Pharmaceuticals, Inc.
CYCC
$7.99
-$0.01-0.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -37.50% | -98.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -37.50% | -98.93% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -37.50% | -98.93% |
| SG&A Expenses | -23.14% | 163.29% | -49.39% | -23.88% | 3.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.90% | 14.87% | -66.09% | -68.12% | -42.11% |
| Operating Income | 63.86% | -15.64% | 65.90% | 68.20% | 38.54% |
| Income Before Tax | 64.13% | 98.12% | 67.36% | 67.66% | 39.19% |
| Income Tax Expenses | 100.49% | -- | 382.94% | 68.56% | 29.69% |
| Earnings from Continuing Operations | 59.53% | 97.25% | 42.10% | 67.56% | 40.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.53% | 97.25% | 42.10% | 67.56% | 40.22% |
| EBIT | 63.86% | -15.64% | 65.90% | 68.20% | 38.54% |
| EBITDA | 63.85% | -15.66% | 65.86% | 68.18% | 38.49% |
| EPS Basic | 99.11% | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | 99.11% | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 4,534.39% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |